Ascentage Pharma Group International (AAPG) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Testing audio. Hello, everyone. Good morning. 1234567. Testing audio. We cannot hear anyone. Hello? Can you hear me? Hello, and welcome to the 2026 interim financial results. We ask that you please hold all questions until the completion of the formal remarks, at which time you will be given instructions for the question and answer session. Also, as a reminder, this conference is being recorded. If you have any objections, please disconnect at this time. With that, I would like to turn the call over to Sumit Neni. You may begin. Thank you, operator, and good morning, everyone. Thank you for joining today. Welcome to Ascentage Pharma's twenty twenty six Interim Results and Business Update Call. I'm Sumit Sunkaraneni, Director of Investor Relations and Corporate Strategy at Ascentage. Please note that today's discussion will include forward looking statements based on our current expectations and assumptions. These statements involve risks and uncertainties, and actual results may differ materially. For a discussion of these risks, please refer to our disclosures. Joining me today are Doctor. Dzheng Yang, our Chairman and Chief Executive Officer Doctor. Faisal Miara, our Chief Business Officer Mr. Jim Zeigler, our Chief Commercial Officer Doctor. Yifan Zai, our Chief Medical Officer and Doctor. Veep Misra, our Chief Financial Officer. Yesterday, we issued a press release with our unaudited financial results for the six months ending 06/30/2026. That release and the slide presentation accompanying this call are available in the Investor Relations section of our website. Turning to our agenda, Doctor. Yang will open with a business update, and we will hear briefly from Doctor. Mihara and Mr. Ziegler on the business development and commercial priorities behind our global ...